Swiss National Bank increased its stake in shares of Catalent Inc (NYSE:CTLT) by 2.3% during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 270,970 shares of the company’s stock after purchasing an additional 6,000 shares during the quarter. Swiss National Bank’s holdings in Catalent were worth $14,689,000 at the end of the most recent quarter.
Several other institutional investors and hedge funds also recently added to or reduced their stakes in CTLT. Dimensional Fund Advisors LP raised its position in Catalent by 4.3% in the fourth quarter. Dimensional Fund Advisors LP now owns 1,326,230 shares of the company’s stock valued at $41,351,000 after purchasing an additional 55,260 shares during the period. Geode Capital Management LLC increased its position in shares of Catalent by 8.2% during the fourth quarter. Geode Capital Management LLC now owns 1,422,860 shares of the company’s stock worth $44,364,000 after acquiring an additional 108,407 shares during the last quarter. Nisa Investment Advisors LLC increased its position in shares of Catalent by 35.7% during the first quarter. Nisa Investment Advisors LLC now owns 22,131 shares of the company’s stock worth $898,000 after acquiring an additional 5,818 shares during the last quarter. Brinker Capital Inc. increased its position in shares of Catalent by 35.1% during the first quarter. Brinker Capital Inc. now owns 44,890 shares of the company’s stock worth $1,822,000 after acquiring an additional 11,668 shares during the last quarter. Finally, Virginia Retirement Systems ET AL increased its position in shares of Catalent by 5.1% during the first quarter. Virginia Retirement Systems ET AL now owns 18,700 shares of the company’s stock worth $759,000 after acquiring an additional 900 shares during the last quarter. 99.94% of the stock is currently owned by institutional investors and hedge funds.
Shares of NYSE CTLT opened at $53.15 on Friday. Catalent Inc has a 1 year low of $29.23 and a 1 year high of $58.38. The firm has a market cap of $8.12 billion, a price-to-earnings ratio of 33.43, a PEG ratio of 2.74 and a beta of 1.64. The company has a debt-to-equity ratio of 1.31, a quick ratio of 1.71 and a current ratio of 2.18. The stock’s 50-day simple moving average is $55.39 and its 200-day simple moving average is $47.32.
In other news, insider Peter L. Buzy acquired 44,500 shares of the stock in a transaction that occurred on Wednesday, May 29th. The stock was purchased at an average cost of $45.13 per share, with a total value of $2,008,285.00. Following the completion of the acquisition, the insider now directly owns 44,500 shares in the company, valued at $2,008,285. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, SVP Steven L. Fasman sold 4,053 shares of the business’s stock in a transaction dated Thursday, July 11th. The shares were sold at an average price of $54.04, for a total value of $219,024.12. The disclosure for this sale can be found here. 1.40% of the stock is currently owned by insiders.
Catalent, Inc provides delivery technologies and development solutions for drugs, biologics, and consumer and animal health products worldwide. It operates through four segments: Softgel Technologies, Biologics and Specialty Drug Delivery, Oral Drug Delivery, and Clinical Supply Services. The Softgel Technologies segment formulates, develops, and manufactures prescription and consumer soft capsules for use in a range of customer products, such as prescription drugs, over-the-counter medications, dietary supplements, unit-dose cosmetics, and animal health medicinal preparations.
Recommended Story: What are different types of coverage ratios?
Want to see what other hedge funds are holding CTLT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Catalent Inc (NYSE:CTLT).
Receive News & Ratings for Catalent Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalent and related companies with MarketBeat.com's FREE daily email newsletter.